NKTR
NEKTAR THERAPEUTICS
- Latest sale
- $15k
- Nov 17 · No plan
- Form 4 sales
- 385
- On record
- Form 144 notices
- 8
- Proposed sales
- Next unlock
- None
- No lockup ahead
Lockups
No lockup on record.
Sales by reason
Timeline
- 1 Form 4 saleNo planMay 19 2026
Sold 199 shares at $65.51 ($13k)
Zalevsky Jonathan, Chief R&D Officer
No 10b5-1 planSold 0.9% of holdings ($1.4M position)20,975 shares left0.1x usual sizeFiling
- 2 Form 4 saleRoutineJun 15 +27 days
Sold 5,538 shares at $60.71 ($336k)
Zalevsky Jonathan, Chief R&D Officer
10b5-1 planSold 26.4% of holdings ($1.3M position)15,437 shares left2x usual sizeFiling
- 3 Form 4 saleRoutineJun 17 +2 days
Sold 20,000 shares at $60.75 ($1.2M)
Robin Howard W, President & CEO
10b5-1 planSold 26.7% of holdings ($4.6M position)55,045 shares left2.2x usual sizeFiling
- 4 Form 4 saleRoutineJun 30 +13 days
Sold 5,681 shares at $70.00 ($398k)
Zalevsky Jonathan, Chief R&D Officer
10b5-1 planSold 36.8% of holdings ($1.1M position)9,756 shares left1.5x usual sizeFiling
- 5 Form 4 saleNo planAug 18 +49 days
Sold 418 shares at $71.98 ($30k)
Robin Howard W, President & CEO
No 10b5-1 planSold 0.8% of holdings ($4M position)54,627 shares left0x usual sizeFiling
- 6 Form 4 saleNo planAug 18 same day
Sold 186 shares at $71.98 ($13k)
Zalevsky Jonathan, Chief R&D Officer
No 10b5-1 planSold 1.9% of holdings ($702k position)9,570 shares left0x usual sizeFiling
- 7 Form 4 saleNo planNov 17 +91 days
Sold 192 shares at $35.85 ($7k)
Zalevsky Jonathan, Chief R&D Officer
No 10b5-1 planSold 2% of holdings ($343k position)9,378 shares left0.1x usual sizeFiling
- 8 Form 4 saleNo planNov 17 same day
Sold 429 shares at $35.85 ($15k)
Robin Howard W, President & CEO
No 10b5-1 planSold 0.8% of holdings ($2M position)54,198 shares left0.1x usual sizeFiling
Every transaction
Loading transactions…
Sales, notices and lockups (393)
Export watchlist as CSV| Source | ||||||||
|---|---|---|---|---|---|---|---|---|
| Nov 17, 2026 | Robin Howard W | President & CEO | Form 4 sale | 429 | $15k | 0.8% | No plan | SEC |
| Nov 17, 2026 | Zalevsky Jonathan | Chief R&D Officer | Form 4 sale | 192 | $7k | 2.0% | No plan | SEC |
| Aug 18, 2026 | Zalevsky Jonathan | Chief R&D Officer | Form 4 sale | 186 | $13k | 1.9% | No plan | SEC |
| Aug 18, 2026 | Robin Howard W | President & CEO | Form 4 sale | 418 | $30k | 0.8% | No plan | SEC |
| Jun 30, 2026 | Zalevsky Jonathan | Chief R&D Officer | Form 4 sale | 5,681 | $398k | 36.8% | Routine | SEC |
| Jun 17, 2026 | Robin Howard W | President & CEO | Form 4 sale | 20,000 | $1.2M | 26.7% | Routine | SEC |
| Jun 15, 2026 | Zalevsky Jonathan | Chief R&D Officer | Form 4 sale | 5,538 | $336k | 26.4% | Routine | SEC |
| May 19, 2026 | Zalevsky Jonathan | Chief R&D Officer | Form 4 sale | 199 | $13k | 0.9% | No plan | SEC |
| May 19, 2026 | Robin Howard W | President & CEO | Form 4 sale | 444 | $29k | 0.6% | No plan | SEC |
| Feb 18, 2026 | Zalevsky Jonathan | Chief R&D Officer | Form 4 sale | 180 | $13k | 0.8% | No plan | SEC |
| Feb 18, 2026 | Robin Howard W | President & CEO | Form 4 sale | 423 | $31k | 0.6% | No plan | SEC |
| Jan 20, 2026 | Zalevsky Jonathan | Chief R&D Officer | Form 4 sale | 3,867 | $138k | 15.3% | Routine | SEC |
| Nov 25, 2025 | Zalevsky Jonathan | Chief R&D Officer | Form 4 sale | 1,157 | $63k | 5.7% | No plan | SEC |
| Nov 25, 2025 | Wilson Mark Andrew | Chief Legal Officer | Form 4 sale | 630 | $34k | 2.8% | No plan | SEC |
| Nov 25, 2025 | Robin Howard W | President & CEO | Form 4 sale | 2,207 | $120k | 3.9% | No plan | SEC |
| Sep 9, 2025 | Robin Howard W | President & CEO | Form 4 sale | 6,666 | $311k | 11.9% | Routine | SEC |
| Sep 5, 2025 | Robin Howard W | President & CEO | Form 4 sale | 11,832 | $431k | 17.4% | Routine | SEC |
| Sep 4, 2025 | Zalevsky Jonathan | Chief R&D Officer | Form 4 sale | 1,721 | $58k | 9.0% | Routine | SEC |
| Sep 2, 2025 | Zalevsky Jonathan | Chief R&D Officer | Form 4 sale | 485 | $15k | 2.5% | Routine | SEC |
| Sep 2, 2025 | Robin Howard W | President & CEO | Form 4 sale | 1,500 | $45k | 2.2% | Routine | SEC |
| Aug 19, 2025 | Zalevsky Jonathan | Chief R&D Officer | Form 4 sale | 725 | $19k | 3.6% | No plan | SEC |
| Aug 19, 2025 | Wilson Mark Andrew | Chief Legal Officer | Form 4 sale | 676 | $18k | 3.2% | No plan | SEC |
| Aug 19, 2025 | Robin Howard W | President & CEO | Form 4 sale | 1,573 | $42k | 2.2% | No plan | SEC |
| May 19, 2025 | Zalevsky Jonathan | Chief R&D Officer | Form 4 sale | 10,712 | $7k | 3.4% | No plan | SEC |
| May 19, 2025 | Wilson Mark Andrew | Chief Legal Officer | Form 4 sale | 9,996 | $7k | 3.1% | No plan | SEC |
| May 19, 2025 | Robin Howard W | President & CEO | Form 4 sale | 23,208 | $16k | 2.1% | No plan | SEC |
| Feb 19, 2025 | Zalevsky Jonathan | Chief R&D Officer | Form 4 sale | 10,300 | $10k | 3.2% | No plan | SEC |
| Feb 19, 2025 | Wilson Mark Andrew | Chief Legal Officer | Form 4 sale | 11,040 | $11k | 3.3% | No plan | SEC |
| Feb 19, 2025 | Robin Howard W | President & CEO | Form 4 sale | 23,774 | $24k | 2.1% | No plan | SEC |
| Dec 24, 2024 | Wilson Mark Andrew | Chief Legal Officer | Form 4 sale | 49,962 | $45k | 13.0% | Unusual | SEC |
| Dec 19, 2024 | Zalevsky Jonathan | Chief R&D Officer | Form 4 sale | 51,115 | $48k | 13.5% | Unusual | SEC |
| Dec 19, 2024 | Zalevsky Jonathan | Officer | Form 144 notice | 51,115 | $48k | Notice | SEC | |
| Dec 18, 2024 | Robin Howard W | President & CEO | Form 4 sale | 132,030 | $132k | 10.6% | No plan | SEC |
| Dec 18, 2024 | Robin Howard W | Officer, Director | Form 144 notice | 85,035 | $84k | Notice | SEC | |
| Dec 17, 2024 | Robin Howard W | Officer, Director | Form 144 notice | 46,995 | $47k | Notice | SEC | |
| Nov 19, 2024 | Zalevsky Jonathan | Chief R&D Officer | Form 4 sale | 7,785 | $8k | 3.1% | No plan | SEC |
| Nov 19, 2024 | Wilson Mark Andrew | Chief Legal Officer | Form 4 sale | 6,407 | $6k | 2.8% | No plan | SEC |
| Nov 19, 2024 | Robin Howard W | President & CEO | Form 4 sale | 16,278 | $16k | 1.9% | No plan | SEC |
| Aug 19, 2024 | Zalevsky Jonathan | Chief R&D Officer | Form 4 sale | 6,866 | $9k | 2.7% | No plan | SEC |
| Aug 19, 2024 | Wilson Mark Andrew | Chief Legal Officer | Form 4 sale | 5,651 | $7k | 2.4% | No plan | SEC |
| Aug 19, 2024 | Robin Howard W | President & CEO | Form 4 sale | 14,881 | $19k | 1.7% | No plan | SEC |
| Jun 14, 2024 | Chess Robert | Director | Form 4 sale | 19,500 | $23k | 7.1% | Routine | SEC |
| May 17, 2024 | Robin Howard W | President & CEO | Form 4 sale | 16,650 | $29k | 1.9% | No plan | SEC |
| May 17, 2024 | Zalevsky Jonathan | Chief R&D Officer | Form 4 sale | 7,355 | $13k | 2.8% | No plan | SEC |
| May 17, 2024 | Wilson Mark Andrew | Chief Legal Officer | Form 4 sale | 6,260 | $11k | 2.6% | No plan | SEC |
| May 10, 2024 | Kroin David | 10% owner | Form 4 sale | 56,000 | $100k | 0.3% | No plan | SEC |
| Feb 20, 2024 | Zalevsky Jonathan | Chief R&D Officer | Form 4 sale | 9,014 | $6k | 3.3% | No plan | SEC |
| Feb 20, 2024 | Wilson Mark Andrew | Chief Legal Officer | Form 4 sale | 7,606 | $5k | 3.1% | No plan | SEC |
| Feb 20, 2024 | Robin Howard W | President & CEO | Form 4 sale | 20,033 | $14k | 2.2% | No plan | SEC |
| Nov 17, 2023 | Zalevsky Jonathan | Chief R&D Officer | Form 4 sale | 9,646 | $5k | 3.4% | No plan | SEC |
| Nov 17, 2023 | Wilson Mark Andrew | Chief Legal Officer | Form 4 sale | 7,179 | $4k | 2.9% | No plan | SEC |
| Nov 17, 2023 | Robin Howard W | President & CEO | Form 4 sale | 19,877 | $10k | 2.2% | No plan | SEC |
| Nov 17, 2023 | Zalevsky Jonathan | Officer | Form 144 notice | 9,646 | $5k | Notice | SEC | |
| Nov 17, 2023 | Wilson Mark Andrew | Officer | Form 144 notice | 7,179 | $4k | Notice | SEC | |
| Nov 17, 2023 | Robin Howard W | Officer, Director | Form 144 notice | 19,877 | $10k | Notice | SEC | |
| Sep 18, 2023 | Curet Myriam | Director | Form 4 sale | 4,359 | $3k | 13.7% | No plan | SEC |
| Sep 18, 2023 | Ajer Jeffrey Robert | Director | Form 4 sale | 4,359 | $3k | 11.3% | No plan | SEC |
| Sep 18, 2023 | Chess Robert | Director | Form 144 notice | 10,200 | $7k | Notice | SEC | |
| Aug 16, 2023 | Zalevsky Jonathan | Chief R&D Officer | Form 4 sale | 9,703 | $8k | 3.3% | No plan | SEC |
| Aug 16, 2023 | Wilson Mark Andrew | Chief Legal Officer | Form 4 sale | 7,221 | $6k | 2.8% | No plan | SEC |
| Aug 16, 2023 | Robin Howard W | President & CEO | Form 4 sale | 19,998 | $16k | 2.1% | No plan | SEC |
| Jun 14, 2023 | Whitfield Roy A | Director | Form 4 sale | 30,000 | $17k | 12.2% | Routine | SEC |
| Jun 14, 2023 | Whitfield Roy A | Director | Form 144 notice | 30,000 | $17k | Notice | SEC | |
| May 16, 2023 | Zalevsky Jonathan | Chief R&D Officer | Form 4 sale | 9,791 | $7k | 3.2% | No plan | SEC |
| May 16, 2023 | Wilson Mark Andrew | Chief Legal Officer | Form 4 sale | 7,543 | $5k | 2.8% | No plan | SEC |
| May 16, 2023 | Robin Howard W | President & CEO | Form 4 sale | 20,361 | $15k | 2.1% | No plan | SEC |
| Feb 16, 2023 | Zalevsky Jonathan | Chief R&D Officer | Form 4 sale | 10,484 | $31k | 3.3% | Plan not stated | SEC |
| Feb 16, 2023 | Wilson Mark Andrew | Chief Legal Officer | Form 4 sale | 8,275 | $25k | 3.0% | Plan not stated | SEC |
| Feb 16, 2023 | Thomsen Jillian B. | Chief Financial Officer | Form 4 sale | 10,267 | $31k | 3.2% | Plan not stated | SEC |
| Feb 16, 2023 | Robin Howard W | President & CEO | Form 4 sale | 19,635 | $59k | 2.0% | Plan not stated | SEC |
| Nov 16, 2022 | Zalevsky Jonathan | Chief R&D Officer | Form 4 sale | 13,460 | $48k | 4.1% | Plan not stated | SEC |
| Nov 16, 2022 | Wilson Mark Andrew | Chief Legal Officer | Form 4 sale | 8,690 | $31k | 3.1% | Plan not stated | SEC |
| Nov 16, 2022 | Thomsen Jillian B. | Chief Financial Officer | Form 4 sale | 11,095 | $40k | 3.3% | Plan not stated | SEC |
| Nov 16, 2022 | Robin Howard W | President & CEO | Form 4 sale | 38,014 | $136k | 3.7% | Unusual | SEC |
| Sep 23, 2022 | Curet Myriam | Director | Form 4 sale | 4,198 | $13k | 11.7% | Plan not stated | SEC |
| Sep 23, 2022 | Ajer Jeffrey Robert | Director | Form 4 sale | 4,198 | $13k | 9.8% | Plan not stated | SEC |
| Sep 22, 2022 | Chess Robert | Director | Form 4 sale | 10,200 | $7k | 3.6% | Routine | SEC |
| Sep 22, 2022 | Chess Robert | Director | Form 4 sale | 5,100 | $16k | 2.2% | Plan not stated | SEC |
| Sep 13, 2022 | Eastham Karin | Director | Form 4 sale | 21,267 | $77k | 62.0% | Unusual | SEC |
| Aug 18, 2022 | Zalevsky Jonathan | Chief R&D Officer | Form 4 sale | 73,716 | $343k | 18.4% | Unusual | SEC |
| Aug 16, 2022 | Zalevsky Jonathan | Chief R&D Officer | Form 4 sale | 10,560 | $50k | 2.6% | Plan not stated | SEC |
| Aug 16, 2022 | Wilson Mark Andrew | SVP & General Counsel | Form 4 sale | 3,189 | $15k | 1.1% | Plan not stated | SEC |
| Aug 16, 2022 | Thomsen Jillian B. | SVP & Chief Accounting Officer | Form 4 sale | 2,006 | $10k | 0.6% | Plan not stated | SEC |
| Aug 16, 2022 | Robin Howard W | President & CEO | Form 4 sale | 13,759 | $65k | 1.3% | Plan not stated | SEC |
| May 16, 2022 | Zalevsky Jonathan | Chief R&D Officer | Form 4 sale | 21,673 | $86k | 7.3% | Plan not stated | SEC |
| May 16, 2022 | Wilson Mark Andrew | SVP & General Counsel | Form 4 sale | 3,136 | $12k | 2.6% | Plan not stated | SEC |
| May 16, 2022 | Thomsen Jillian B. | SVP & Chief Accounting Officer | Form 4 sale | 5,841 | $23k | 3.3% | Plan not stated | SEC |
| May 16, 2022 | Robin Howard W | President & CEO | Form 4 sale | 36,529 | $144k | 5.6% | Unusual | SEC |
| May 16, 2022 | Northcott John | SVP & Chief Commercial Officer | Form 4 sale | 4,592 | $18k | 2.0% | Plan not stated | SEC |
| May 16, 2022 | Labrucherie Gil M | SVP, COO & CFO | Form 4 sale | 17,448 | $69k | 5.3% | Plan not stated | SEC |
| Feb 16, 2022 | Zalevsky Jonathan | Chief R&D Officer | Form 4 sale | 10,912 | $119k | 3.8% | Plan not stated | SEC |
| Feb 16, 2022 | Wilson Mark Andrew | SVP & General Counsel | Form 4 sale | 3,661 | $40k | 2.9% | Plan not stated | SEC |
| Feb 16, 2022 | Thomsen Jillian B. | SVP & Chief Accounting Officer | Form 4 sale | 2,363 | $26k | 1.4% | Plan not stated | SEC |
| Feb 16, 2022 | Robin Howard W | President & CEO | Form 4 sale | 12,480 | $137k | 2.1% | Plan not stated | SEC |
| Feb 16, 2022 | Northcott John | SVP & Chief Commercial Officer | Form 4 sale | 4,852 | $53k | 2.1% | Plan not stated | SEC |
| Feb 16, 2022 | Labrucherie Gil M | SVP, COO & CFO | Form 4 sale | 7,579 | $83k | 2.5% | Plan not stated | SEC |
| Nov 18, 2021 | Labrucherie Gil M | SVP, COO & CFO | Form 4 sale | 24,149 | $316k | 8.6% | Plan not stated | SEC |
| Nov 16, 2021 | Zalevsky Jonathan | Chief R&D Officer | Form 4 sale | 20,869 | $275k | 8.3% | Plan not stated | SEC |
| Nov 16, 2021 | Wilson Mark Andrew | SVP & General Counsel | Form 4 sale | 6,564 | $86k | 7.1% | Unusual | SEC |
| Nov 16, 2021 | Thomsen Jillian B. | SVP & Chief Accounting Officer | Form 4 sale | 6,741 | $89k | 4.4% | Plan not stated | SEC |
| Nov 16, 2021 | Robin Howard W | President & CEO | Form 4 sale | 42,773 | $563k | 8.3% | Unusual | SEC |
| Nov 16, 2021 | Northcott John | SVP & Chief Commercial Officer | Form 4 sale | 6,061 | $80k | 3.0% | Plan not stated | SEC |
| Sep 22, 2021 | Curet Myriam | Director | Form 4 sale | 3,665 | $65k | 12.4% | Plan not stated | SEC |
| Sep 22, 2021 | Chess Robert | Director | Form 4 sale | 4,600 | $83k | 1.6% | Plan not stated | SEC |
| Sep 22, 2021 | Ajer Jeffrey Robert | Director | Form 4 sale | 3,665 | $65k | 10.1% | Plan not stated | SEC |
| Sep 9, 2021 | Chess Robert | Director | Form 4 sale | 18,279 | $293k | 6.2% | Plan not stated | SEC |
| Aug 17, 2021 | Labrucherie Gil M | SVP, COO & CFO | Form 4 sale | 10,867 | $149k | 4.3% | Plan not stated | SEC |
| Aug 16, 2021 | Zalevsky Jonathan | Chief R&D Officer | Form 4 sale | 7,662 | $106k | 3.5% | Plan not stated | SEC |
| Aug 16, 2021 | Wilson Mark Andrew | SVP & General Counsel | Form 4 sale | 1,910 | $26k | 2.6% | Plan not stated | SEC |
| Aug 16, 2021 | Robin Howard W | President & CEO | Form 4 sale | 11,515 | $159k | 2.6% | Plan not stated | SEC |
| Aug 16, 2021 | Thomsen Jillian B. | SVP & Chief Accounting Officer | Form 4 sale | 13,339 | $184k | 8.8% | Plan not stated | SEC |
| Aug 16, 2021 | Northcott John | SVP & Chief Commercial Officer | Form 4 sale | 6,192 | $86k | 3.0% | Plan not stated | SEC |
| Jul 22, 2021 | Chess Robert | Director | Form 4 sale | 5,721 | $96k | 2.0% | Plan not stated | SEC |
| May 17, 2021 | Zalevsky Jonathan | Chief R&D Officer | Form 4 sale | 31,111 | $569k | 11.7% | Plan not stated | SEC |
| May 17, 2021 | Wilson Mark Andrew | SVP & General Counsel | Form 4 sale | 1,917 | $35k | 2.5% | Plan not stated | SEC |
| May 17, 2021 | Thomsen Jillian B. | SVP & Chief Accounting Officer | Form 4 sale | 13,391 | $245k | 8.1% | Unusual | SEC |
| May 17, 2021 | Robin Howard W | President & CEO | Form 4 sale | 11,560 | $212k | 2.6% | Plan not stated | SEC |
| May 17, 2021 | Northcott John | SVP & Chief Commercial Officer | Form 4 sale | 6,085 | $111k | 2.9% | Plan not stated | SEC |
| May 17, 2021 | Labrucherie Gil M | SVP, COO & CFO | Form 4 sale | 7,898 | $145k | 3.0% | Plan not stated | SEC |
| May 12, 2021 | Chess Robert | Director | Form 4 sale | 8,000 | $155k | 2.8% | Plan not stated | SEC |
| Apr 14, 2021 | Chess Robert | Director | Form 4 sale | 8,000 | $152k | 2.8% | Plan not stated | SEC |
| Feb 16, 2021 | Zalevsky Jonathan | Chief R&D Officer | Form 4 sale | 24,141 | $540k | 8.3% | Plan not stated | SEC |
| Feb 16, 2021 | Wilson Mark Andrew | SVP & General Counsel | Form 4 sale | 2,173 | $49k | 2.8% | Plan not stated | SEC |
| Feb 16, 2021 | Thomsen Jillian B. | SVP & Chief Accounting Officer | Form 4 sale | 11,705 | $262k | 6.6% | Unusual | SEC |
| Feb 16, 2021 | Robin Howard W | President & CEO | Form 4 sale | 11,495 | $257k | 2.5% | Plan not stated | SEC |
| Feb 16, 2021 | Northcott John | SVP & Chief Commercial Officer | Form 4 sale | 15,358 | $344k | 6.7% | Plan not stated | SEC |
| Feb 16, 2021 | Labrucherie Gil M | SVP, COO & CFO | Form 4 sale | 7,977 | $178k | 3.0% | Plan not stated | SEC |
| Feb 4, 2021 | Robin Howard W | President & CEO | Form 4 sale | 450,000 | $9M | 49.5% | Unusual | SEC |
| Feb 4, 2021 | Labrucherie Gil M | SVP, COO & CFO | Form 4 sale | 150,000 | $3M | 36.0% | Unusual | SEC |
| Feb 3, 2021 | Wilson Mark Andrew | SVP & General Counsel | Form 4 sale | 5,344 | $104k | 6.3% | Unusual | SEC |
| Jan 28, 2021 | Thomsen Jillian B. | SVP & Chief Accounting Officer | Form 4 sale | 75,000 | $1.4M | 29.8% | Unusual | SEC |
| Dec 15, 2020 | Myriam Curet | Director | Form 4 sale | 1,560 | $28k | 7.5% | Plan not stated | SEC |
| Nov 23, 2020 | Zalevsky Jonathan | Chief R&D Officer | Form 4 sale | 16,380 | $269k | 6.1% | Unusual | SEC |
| Nov 16, 2020 | Zalevsky Jonathan | Chief R&D Officer | Form 4 sale | 29,618 | $501k | 10.0% | Unusual | SEC |
| Nov 16, 2020 | Wilson Mark Andrew | SVP & General Counsel | Form 4 sale | 1,539 | $26k | 3.0% | Plan not stated | SEC |
| Nov 16, 2020 | Thomsen Jillian B. | SVP & Chief Accounting Officer | Form 4 sale | 11,976 | $203k | 7.0% | Unusual | SEC |
| Nov 16, 2020 | Robin Howard W | President & CEO | Form 4 sale | 11,975 | $203k | 3.3% | Plan not stated | SEC |
| Nov 16, 2020 | Labrucherie Gil M | SVP, COO & CFO | Form 4 sale | 8,276 | $140k | 3.5% | Plan not stated | SEC |
| Sep 28, 2020 | Ajer Jeffrey Robert | Director | Form 4 sale | 3,250 | $56k | 11.1% | Plan not stated | SEC |
| Sep 25, 2020 | Chess Robert | Director | Form 4 sale | 5,500 | $98k | 1.9% | Plan not stated | SEC |
| Sep 21, 2020 | Ajer Jeffrey Robert | Director | Form 4 sale | 2,250 | $44k | 10.1% | Plan not stated | SEC |
| Sep 17, 2020 | Labrucherie Gil M | SVP, COO & CFO | Form 4 sale | 2,000 | $40k | 0.8% | Plan not stated | SEC |
| Sep 8, 2020 | Chess Robert | Director | Form 4 sale | 8,000 | $148k | 2.8% | Plan not stated | SEC |
| Aug 18, 2020 | Labrucherie Gil M | SVP, COO & CFO | Form 4 sale | 8,245 | $162k | 3.4% | Plan not stated | SEC |
| Aug 17, 2020 | Zalevsky Jonathan | Chief R&D Officer | Form 4 sale | 26,200 | $515k | 8.1% | Unusual | SEC |
| Aug 17, 2020 | Wilson Mark Andrew | SVP & General Counsel | Form 4 sale | 1,529 | $30k | 2.9% | Plan not stated | SEC |
| Aug 17, 2020 | Thomsen Jillian B. | SVP & Chief Accounting Officer | Form 4 sale | 1,367 | $27k | 0.8% | Plan not stated | SEC |
| Aug 17, 2020 | Robin Howard W | President & CEO | Form 4 sale | 11,885 | $234k | 3.2% | Plan not stated | SEC |
| Jul 9, 2020 | Greer R Scott | Director | Form 4 sale | 15,009 | $375k | 7.8% | Plan not stated | SEC |
| Jul 8, 2020 | Chess Robert | Director | Form 4 sale | 8,000 | $197k | 2.8% | Plan not stated | SEC |
| May 19, 2020 | Labrucherie Gil M | SVP, COO & CFO | Form 4 sale | 7,727 | $174k | 3.1% | Plan not stated | SEC |
| May 18, 2020 | Zalevsky Jonathan | Chief R&D Officer | Form 4 sale | 4,558 | $103k | 1.4% | Plan not stated | SEC |
| May 18, 2020 | Wilson Mark Andrew | SVP & General Counsel | Form 4 sale | 1,529 | $34k | 2.8% | Plan not stated | SEC |
| May 18, 2020 | Thomsen Jillian B. | SVP & Chief Accounting Officer | Form 4 sale | 1,367 | $31k | 0.8% | Plan not stated | SEC |
| May 18, 2020 | Robin Howard W | President & CEO | Form 4 sale | 8,968 | $202k | 2.3% | Plan not stated | SEC |
| Apr 15, 2020 | Chess Robert | Director | Form 4 sale | 8,000 | $147k | 2.8% | Plan not stated | SEC |
| Mar 11, 2020 | Chess Robert | Director | Form 4 sale | 8,000 | $134k | 2.8% | Plan not stated | SEC |
| Feb 18, 2020 | Zalevsky Jonathan | Chief R&D Officer | Form 4 sale | 4,774 | $107k | 1.4% | Plan not stated | SEC |
| Feb 18, 2020 | Thomsen Jillian B. | SVP & Chief Accounting Officer | Form 4 sale | 1,394 | $31k | 0.8% | Plan not stated | SEC |
| Feb 18, 2020 | Robin Howard W | President & CEO | Form 4 sale | 8,448 | $189k | 2.1% | Plan not stated | SEC |
| Feb 18, 2020 | Labrucherie Gil M | SVP, COO & CFO | Form 4 sale | 5,938 | $133k | 2.3% | Plan not stated | SEC |
| Feb 12, 2020 | Chess Robert | Director | Form 4 sale | 8,000 | $188k | 2.8% | Plan not stated | SEC |
| Feb 6, 2020 | Thomsen Jillian B. | SVP & Chief Accounting Officer | Form 4 sale | 37,500 | $854k | 17.6% | Unusual | SEC |
| Nov 18, 2019 | Zalevsky Jonathan | Chief R&D Officer | Form 4 sale | 3,960 | $71k | 1.3% | Plan not stated | SEC |
| Nov 18, 2019 | Thomsen Jillian B. | SVP & Chief Accounting Officer | Form 4 sale | 2,713 | $49k | 1.7% | Plan not stated | SEC |
| Nov 18, 2019 | Robin Howard W | President & CEO | Form 4 sale | 13,556 | $244k | 4.3% | Plan not stated | SEC |
| Nov 18, 2019 | Labrucherie Gil M | SVP, COO & CFO | Form 4 sale | 8,863 | $159k | 3.9% | Plan not stated | SEC |
| Nov 13, 2019 | Labrucherie Gil M | SVP, COO & CFO | Form 4 sale | 25,000 | $495k | 9.9% | Plan not stated | SEC |
| Oct 17, 2019 | Robin Howard W | President & CEO | Form 4 sale | 100,000 | $1.7M | 24.2% | Plan not stated | SEC |
| Oct 15, 2019 | Labrucherie Gil M | SVP, COO & CFO | Form 4 sale | 25,000 | $396k | 9.9% | Unusual | SEC |
| Sep 30, 2019 | Ajer Jeffrey Robert | Director | Form 4 sale | 2,375 | $43k | 9.6% | Plan not stated | SEC |
| Sep 27, 2019 | Lingnau Lutz | Director | Form 4 sale | 3,000 | $54k | 10.1% | Plan not stated | SEC |
| Sep 27, 2019 | Chess Robert | Director | Form 4 sale | 4,000 | $72k | 1.4% | Plan not stated | SEC |
| Sep 20, 2019 | Ajer Jeffrey Robert | Director | Form 4 sale | 2,250 | $46k | 11.0% | Plan not stated | SEC |
| Sep 16, 2019 | Labrucherie Gil M | SVP & Chief Financial Officer | Form 4 sale | 25,000 | $513k | 14.1% | Unusual | SEC |
| Aug 16, 2019 | Thomsen Jillian B. | SVP & Chief Accounting Officer | Form 4 sale | 1,809 | $33k | 1.1% | Plan not stated | SEC |
| Aug 16, 2019 | Robin Howard W | President & CEO | Form 4 sale | 12,551 | $228k | 4.2% | Plan not stated | SEC |
| Aug 16, 2019 | Nicholson John | SVP & Chief Operating Officer | Form 4 sale | 3,819 | $69k | 2.3% | Plan not stated | SEC |
| Aug 16, 2019 | Labrucherie Gil M | SVP & Chief Financial Officer | Form 4 sale | 5,063 | $92k | 4.0% | Plan not stated | SEC |
| Aug 16, 2019 | Doberstein Stephen K | SVP & Chief Scientific Officer | Form 4 sale | 3,245 | $59k | 3.4% | Plan not stated | SEC |
| Aug 14, 2019 | Labrucherie Gil M | SVP & Chief Financial Officer | Form 4 sale | 25,000 | $445k | 16.3% | Unusual | SEC |
| Jul 25, 2019 | Robin Howard W | President & CEO | Form 4 sale | 100,000 | $3.1M | 25.3% | Unusual | SEC |
| Jul 10, 2019 | Labrucherie Gil M | SVP & Chief Financial Officer | Form 4 sale | 25,000 | $864k | 16.3% | Unusual | SEC |
| Jul 8, 2019 | Lingnau Lutz | Director | Form 4 sale | 10,000 | $346k | 30.1% | Unusual | SEC |
| Jun 17, 2019 | Labrucherie Gil M | SVP & Chief Financial Officer | Form 4 sale | 25,000 | $843k | 16.3% | Unusual | SEC |
| May 23, 2019 | Robin Howard W | President & CEO | Form 4 sale | 100,000 | $3.3M | 25.3% | Unusual | SEC |
| May 16, 2019 | Thomsen Jillian B. | SVP & Chief Accounting Officer | Form 4 sale | 1,928 | $60k | 1.2% | Plan not stated | SEC |
| May 16, 2019 | Robin Howard W | President & CEO | Form 4 sale | 13,383 | $420k | 4.3% | Plan not stated | SEC |
| May 16, 2019 | Nicholson John | SVP & Chief Operating Officer | Form 4 sale | 4,077 | $128k | 2.4% | Plan not stated | SEC |
| May 16, 2019 | Labrucherie Gil M | SVP & Chief Financial Officer | Form 4 sale | 3,767 | $118k | 2.9% | Plan not stated | SEC |
| May 16, 2019 | Hora Maninder | SVP Pharma Dev & Mfg Ops | Form 4 sale | 2,449 | $77k | 2.5% | Plan not stated | SEC |
| May 16, 2019 | Doberstein Stephen K | SVP & Chief Scientific Officer | Form 4 sale | 3,461 | $109k | 3.5% | Plan not stated | SEC |
| Feb 21, 2019 | Robin Howard W | President & CEO | Form 4 sale | 108,882 | $4.6M | 26.1% | Unusual | SEC |
| Feb 19, 2019 | Thomsen Jillian B. | SVP & Chief Accounting Officer | Form 4 sale | 1,808 | $77k | 1.1% | Plan not stated | SEC |
| Feb 19, 2019 | Nicholson John | SVP & Chief Operating Officer | Form 4 sale | 3,822 | $162k | 2.2% | Plan not stated | SEC |
| Feb 19, 2019 | Labrucherie Gil M | SVP & Chief Financial Officer | Form 4 sale | 3,592 | $152k | 2.7% | Plan not stated | SEC |
| Feb 19, 2019 | Hora Maninder | SVP Pharma Dev & Mfg Ops | Form 4 sale | 2,386 | $101k | 2.4% | Plan not stated | SEC |
| Feb 19, 2019 | Doberstein Stephen K | SVP & Chief Scientific Officer | Form 4 sale | 3,310 | $140k | 3.2% | Plan not stated | SEC |
| Feb 4, 2019 | Thomsen Jillian B. | SVP & Chief Accounting Officer | Form 4 sale | 16,119 | $680k | 8.7% | Unusual | SEC |
| Jan 28, 2019 | Nicholson John | SVP & Chief Operating Officer | Form 4 sale | 63,000 | $2.7M | 26.5% | Unusual | SEC |
| Nov 16, 2018 | Thomsen Jillian B. | SVP & Chief Accounting Officer | Form 4 sale | 4,016 | $154k | 2.5% | Plan not stated | SEC |
| Nov 16, 2018 | Robin Howard W | President & CEO | Form 4 sale | 15,326 | $586k | 5.8% | Plan not stated | SEC |
| Nov 16, 2018 | Nicholson John | SVP & Chief Operating Officer | Form 4 sale | 5,982 | $229k | 3.3% | Plan not stated | SEC |
| Nov 16, 2018 | Labrucherie Gil M | SVP & Chief Financial Officer | Form 4 sale | 6,515 | $249k | 5.8% | Plan not stated | SEC |
| Nov 16, 2018 | Hora Maninder | SVP Pharma Dev & Mfg Ops | Form 4 sale | 4,694 | $180k | 5.5% | Plan not stated | SEC |
| Nov 16, 2018 | Doberstein Stephen K | SVP & Chief Scientific Officer | Form 4 sale | 4,524 | $173k | 5.4% | Plan not stated | SEC |
| Sep 20, 2018 | Lingnau Lutz | Director | Form 4 sale | 9,000 | $513k | 32.8% | Unusual | SEC |
| Sep 20, 2018 | Ajer Jeffrey Robert | Director | Form 4 sale | 6,750 | $383k | 30.0% | Unusual | SEC |
| Sep 19, 2018 | Chess Robert | Director | Form 4 sale | 4,500 | $256k | 1.6% | Plan not stated | SEC |
| Sep 4, 2018 | Greer R Scott | Director | Form 4 sale | 10,000 | $674k | 7.1% | Plan not stated | SEC |
| Aug 21, 2018 | Winger Dennis L | Director | Form 4 sale | 30,000 | $1.8M | 41.2% | Unusual | SEC |
| Aug 14, 2018 | Winger Dennis L | Director | Form 4 sale | 34,250 | $2.1M | 44.5% | Unusual | SEC |
| Jun 27, 2018 | Robin Howard W | President & CEO | Form 4 sale | 130,000 | $6.4M | 36.7% | Unusual | SEC |
| Jun 6, 2018 | Greer R Scott | Director | Form 4 sale | 10,000 | $603k | 7.1% | Plan not stated | SEC |
| Jun 5, 2018 | Chess Robert | Director | Form 4 sale | 10,000 | $552k | 3.5% | Plan not stated | SEC |
| May 16, 2018 | Thomsen Jillian B. | SVP & Chief Accounting Officer | Form 4 sale | 3,576 | $298k | 5.2% | Plan not stated | SEC |
| May 16, 2018 | Robin Howard W | President & CEO | Form 4 sale | 12,791 | $1.1M | 5.4% | Plan not stated | SEC |
| May 16, 2018 | Nicholson John | SVP & Chief Operating Officer | Form 4 sale | 4,917 | $410k | 2.9% | Plan not stated | SEC |
| May 16, 2018 | Labrucherie Gil M | SVP & Chief Financial Officer | Form 4 sale | 4,941 | $412k | 5.0% | Plan not stated | SEC |
| May 16, 2018 | Hora Maninder | SVP Pharma Dev & Mfg Ops | Form 4 sale | 4,060 | $339k | 5.1% | Plan not stated | SEC |
| May 16, 2018 | Doberstein Stephen K | SVP & Chief Scientific Officer | Form 4 sale | 3,435 | $286k | 5.1% | Plan not stated | SEC |
| May 3, 2018 | Chess Robert | Director | Form 4 sale | 25,000 | $2.1M | 8.4% | Unusual | SEC |
| May 3, 2018 | Labrucherie Gil M | SVP & Chief Financial Officer | Form 4 sale | 90,000 | $7.6M | 47.4% | Unusual | SEC |
| May 3, 2018 | Robin Howard W | President & CEO | Form 4 sale | 130,000 | $10.9M | 35.4% | Unusual | SEC |
| Apr 16, 2018 | Thomsen Jillian B. | SVP & Chief Accounting Officer | Form 4 sale | 13,881 | $1.4M | 16.8% | Unusual | SEC |
| Apr 10, 2018 | Hora Maninder | SVP Pharma Dev & Mfg Ops | Form 4 sale | 502 | $53k | 0.6% | Plan not stated | SEC |
| Apr 9, 2018 | Hora Maninder | SVP Pharma Dev & Mfg Ops | Form 4 sale | 29,498 | $3M | 26.9% | Unusual | SEC |
| Apr 9, 2018 | Doberstein Stephen K | SVP & Chief Scientific Officer | Form 4 sale | 160,000 | $14.9M | 70.4% | Unusual | SEC |
| Apr 6, 2018 | Greer R Scott | Director | Form 4 sale | 30,000 | $2.8M | 18.7% | Plan not stated | SEC |
| Apr 6, 2018 | Chess Robert | Director | Form 4 sale | 25,000 | $2.3M | 8.4% | Unusual | SEC |
| Apr 5, 2018 | Lingnau Lutz | Director | Form 4 sale | 30,000 | $3.1M | 52.2% | Unusual | SEC |
| Mar 7, 2018 | Kuebler Christopher A | Director | Form 4 sale | 40,000 | $3.9M | 49.7% | Unusual | SEC |
| Mar 7, 2018 | Nicholson John | SVP & Chief Operating Officer | Form 4 sale | 220,144 | $21.9M | 56.8% | Unusual | SEC |
| Feb 16, 2018 | Thomsen Jillian B. | SVP & Chief Accounting Officer | Form 4 sale | 2,545 | $211k | 3.6% | Plan not stated | SEC |
| Feb 16, 2018 | Robin Howard W | President & CEO | Form 4 sale | 12,788 | $1.1M | 5.1% | Plan not stated | SEC |
| Feb 16, 2018 | Nicholson John | SVP & Chief Operating Officer | Form 4 sale | 4,879 | $405k | 1.2% | Plan not stated | SEC |
| Feb 16, 2018 | Labrucherie Gil M | SVP & Chief Financial Officer | Form 4 sale | 3,477 | $288k | 3.4% | Plan not stated | SEC |
| Feb 16, 2018 | Hora Maninder | SVP Pharma Dev & Mfg Ops | Form 4 sale | 2,875 | $238k | 3.5% | Plan not stated | SEC |
| Feb 16, 2018 | Doberstein Stephen K | SVP & Chief Scientific Officer | Form 4 sale | 2,426 | $201k | 3.5% | Plan not stated | SEC |
| Jan 22, 2018 | Robin Howard W | President & CEO | Form 4 sale | 83,333 | $6.3M | 25.0% | Unusual | SEC |
| Jan 2, 2018 | Kuebler Christopher A | Director | Form 4 sale | 30,000 | $1.8M | 42.6% | Unusual | SEC |
| Dec 13, 2017 | Robin Howard W | President & CEO | Form 4 sale | 83,333 | $4.6M | 30.6% | Unusual | SEC |
| Nov 13, 2017 | Nicholson John | SVP & Chief Operating Officer | Form 4 sale | 15,910 | $601k | 6.4% | Unusual | SEC |
| Nov 8, 2017 | Doberstein Stephen K | SVP & Chief Scientific Officer | Form 4 sale | 396,323 | $11.5M | 92.7% | Unusual | SEC |
| Nov 6, 2017 | Hora Maninder | SVP Pharma Dev & Mfg Ops | Form 4 sale | 5,117 | $128k | 8.1% | Plan not stated | SEC |
| Nov 1, 2017 | Robin Howard W | President & CEO | Form 4 sale | 83,334 | $2M | 35.3% | Unusual | SEC |
| Oct 9, 2017 | Robin Howard W | President & CEO | Form 4 sale | 83,333 | $2M | 35.3% | Unusual | SEC |
| Oct 5, 2017 | Hora Maninder | SVP Pharma Dev & Mfg Ops | Form 4 sale | 7,583 | $190k | 11.5% | Plan not stated | SEC |
| Oct 5, 2017 | Doberstein Stephen K | SVP & Chief Scientific Officer | Form 4 sale | 43,677 | $1.1M | 58.4% | Unusual | SEC |
| Oct 2, 2017 | Labrucherie Gil M | SVP & Chief Financial Officer | Form 4 sale | 120,000 | $2.9M | 65.4% | Unusual | SEC |
| Oct 2, 2017 | Gergel Ivan P. | SVP & Chief Medical Officer | Form 4 sale | 100,000 | $2.4M | 70.6% | Unusual | SEC |
| Sep 22, 2017 | Lingnau Lutz | Director | Form 4 sale | 5,000 | $110k | 15.4% | Plan not stated | SEC |
| Sep 22, 2017 | Kuebler Christopher A | Director | Form 4 sale | 4,000 | $87k | 9.0% | Plan not stated | SEC |
| Sep 21, 2017 | Chess Robert | Director | Form 4 sale | 6,400 | $139k | 2.3% | Plan not stated | SEC |
| Sep 6, 2017 | Robin Howard W | President & CEO | Form 4 sale | 83,333 | $1.8M | 35.3% | Unusual | SEC |
| Aug 16, 2017 | Thomsen Jillian B. | SVP & Chief Accounting Officer | Form 4 sale | 2,648 | $51k | 5.0% | Plan not stated | SEC |
| Aug 16, 2017 | Robin Howard W | President & CEO | Form 4 sale | 91,714 | $1.8M | 37.6% | Unusual | SEC |
| Aug 16, 2017 | Nicholson John | SVP & Chief Operating Officer | Form 4 sale | 3,177 | $61k | 1.4% | Plan not stated | SEC |
| Aug 16, 2017 | Labrucherie Gil M | SVP & Chief Financial Officer | Form 4 sale | 3,177 | $61k | 4.8% | Plan not stated | SEC |
| Aug 16, 2017 | Hora Maninder | SVP Pharma Dev & Mfg Ops | Form 4 sale | 2,956 | $57k | 4.8% | Plan not stated | SEC |
| Aug 16, 2017 | Gergel Ivan P. | SVP & Chief Medical Officer | Form 4 sale | 1,997 | $39k | 4.6% | Plan not stated | SEC |
| Aug 16, 2017 | Doberstein Stephen K | SVP & Chief Scientific Officer | Form 4 sale | 1,701 | $33k | 5.2% | Plan not stated | SEC |
| Jul 18, 2017 | Gergel Ivan P. | SVP & Chief Medical Officer | Form 4 sale | 54,920 | $1.2M | 55.8% | Unusual | SEC |
| Jul 14, 2017 | Lingnau Lutz | Director | Form 4 sale | 30,000 | $623k | 56.1% | Unusual | SEC |
| Jul 12, 2017 | Gergel Ivan P. | SVP & Chief Medical Officer | Form 4 sale | 45,080 | $950k | 50.9% | Unusual | SEC |
| Jun 7, 2017 | Nicholson John | SVP & Chief Operating Officer | Form 4 sale | 101,700 | $2M | 30.9% | Unusual | SEC |
| May 16, 2017 | Thomsen Jillian B. | SVP & Chief Accounting Officer | Form 4 sale | 2,651 | $52k | 4.8% | Plan not stated | SEC |
| May 16, 2017 | Robin Howard W | President & CEO | Form 4 sale | 8,388 | $164k | 5.0% | Plan not stated | SEC |
| May 16, 2017 | Nicholson John | SVP & Chief Operating Officer | Form 4 sale | 3,146 | $62k | 1.7% | Plan not stated | SEC |
| May 16, 2017 | Labrucherie Gil M | SVP & Chief Financial Officer | Form 4 sale | 3,179 | $62k | 4.6% | Plan not stated | SEC |
| May 16, 2017 | Hora Maninder | SVP Pharma Dev & Mfg Ops | Form 4 sale | 2,959 | $58k | 4.6% | Plan not stated | SEC |
| May 16, 2017 | Gergel Ivan P. | SVP & Chief Medical Officer | Form 4 sale | 1,450 | $28k | 3.2% | Plan not stated | SEC |
| May 16, 2017 | Doberstein Stephen K | SVP & Chief Scientific Officer | Form 4 sale | 1,701 | $33k | 4.9% | Plan not stated | SEC |
| May 15, 2017 | Chess Robert | Director | Form 4 sale | 5,000 | $99k | 1.8% | Plan not stated | SEC |
| Apr 17, 2017 | Chess Robert | Director | Form 4 sale | 5,000 | $94k | 1.8% | Plan not stated | SEC |
| Apr 7, 2017 | Lingnau Lutz | Director | Form 4 sale | 7,000 | $140k | 23.0% | Plan not stated | SEC |
| Apr 5, 2017 | Doberstein Stephen K | SVP & Chief Scientific Officer | Form 4 sale | 100,000 | $2.2M | 74.3% | Unusual | SEC |
| Apr 5, 2017 | Hora Maninder | SVP Pharma Dev & Mfg Ops | Form 4 sale | 180,000 | $3.9M | 73.9% | Unusual | SEC |
| Apr 5, 2017 | Kuebler Christopher A | Director | Form 4 sale | 15,000 | $328k | 29.7% | Unusual | SEC |
| Mar 20, 2017 | Thomsen Jillian B. | SVP & Chief Accounting Officer | Form 4 sale | 112,500 | $2.2M | 66.9% | Unusual | SEC |
| Mar 14, 2017 | Chess Robert | Director | Form 4 sale | 5,000 | $77k | 1.8% | Plan not stated | SEC |
| Mar 3, 2017 | Labrucherie Gil M | SVP & Chief Financial Officer | Form 4 sale | 200,000 | $3M | 74.3% | Unusual | SEC |
| Feb 21, 2017 | Lingnau Lutz | Director | Form 4 sale | 30,000 | $392k | 49.6% | Unusual | SEC |
| Feb 16, 2017 | Thomsen Jillian B. | SVP & Chief Accounting Officer | Form 4 sale | 1,965 | $26k | 3.4% | Plan not stated | SEC |
| Feb 16, 2017 | Robin Howard W | President & CEO | Form 4 sale | 8,636 | $113k | 4.9% | Plan not stated | SEC |
| Feb 16, 2017 | Nicholson John | SVP & Chief Operating Officer | Form 4 sale | 3,237 | $43k | 1.7% | Plan not stated | SEC |
| Feb 16, 2017 | Labrucherie Gil M | SVP & Chief Financial Officer | Form 4 sale | 2,359 | $31k | 3.3% | Plan not stated | SEC |
| Feb 16, 2017 | Hora Maninder | SVP Pharma Dev & Mfg Ops | Form 4 sale | 2,195 | $29k | 3.3% | Plan not stated | SEC |
| Feb 16, 2017 | Gergel Ivan P. | SVP & Chief Medical Officer | Form 4 sale | 1,457 | $19k | 3.1% | Plan not stated | SEC |
| Feb 16, 2017 | Doberstein Stephen K | SVP & Chief Scientific Officer | Form 4 sale | 1,261 | $17k | 3.5% | Plan not stated | SEC |
| Feb 8, 2017 | Robin Howard W | President & CEO | Form 4 sale | 87,500 | $1.1M | 33.0% | Unusual | SEC |
| Feb 3, 2017 | Nicholson John | SVP & Chief Operating Officer | Form 4 sale | 75,000 | $929k | 34.8% | Unusual | SEC |
| Jan 17, 2017 | Robin Howard W | President & CEO | Form 4 sale | 87,500 | $1.1M | 33.0% | Unusual | SEC |
| Dec 7, 2016 | Robin Howard W | President & CEO | Form 4 sale | 87,500 | $1.1M | 41.6% | Unusual | SEC |
| Nov 17, 2016 | Robin Howard W | President & CEO | Form 4 sale | 93,458 | $1.3M | 43.2% | Unusual | SEC |
| Nov 16, 2016 | Thomsen Jillian B. | SVP & Chief Accounting Officer | Form 4 sale | 1,986 | $28k | 4.5% | Plan not stated | SEC |
| Nov 16, 2016 | Nicholson John | SVP & Chief Operating Officer | Form 4 sale | 1,654 | $23k | 1.4% | Plan not stated | SEC |
| Nov 16, 2016 | Labrucherie Gil M | SVP & Chief Financial Officer | Form 4 sale | 1,654 | $23k | 3.1% | Plan not stated | SEC |
| Nov 16, 2016 | Hora Maninder | SVP Pharma Dev & Mfg Ops | Form 4 sale | 1,654 | $23k | 3.2% | Plan not stated | SEC |
| Nov 16, 2016 | Gergel Ivan P. | SVP & Chief Medical Officer | Form 4 sale | 848 | $12k | 3.1% | Plan not stated | SEC |
| Nov 16, 2016 | Doberstein Stephen K | SVP & Chief Scientific Officer | Form 4 sale | 670 | $9k | 3.5% | Plan not stated | SEC |
| Oct 4, 2016 | Robin Howard W | President & CEO | Form 4 sale | 87,500 | $1.5M | 40.4% | Unusual | SEC |
| Sep 16, 2016 | Kuebler Christopher A | Director | Form 4 sale | 7,500 | $143k | 21.4% | Plan not stated | SEC |
| Sep 15, 2016 | Lingnau Lutz | Director | Form 4 sale | 9,000 | $172k | 54.7% | Unusual | SEC |
| Sep 15, 2016 | Chess Robert | Director | Form 4 sale | 12,000 | $231k | 4.6% | Plan not stated | SEC |
| Sep 1, 2016 | Robin Howard W | President & CEO | Form 4 sale | 87,500 | $1.6M | 40.4% | Unusual | SEC |
| Aug 16, 2016 | Nicholson John | SVP & Chief Operating Officer | Form 4 sale | 3,317 | $58k | 2.6% | Unusual | SEC |
| Aug 16, 2016 | Thomsen Jillian B. | SVP & Chief Accounting Officer | Form 4 sale | 3,971 | $70k | 8.3% | Plan not stated | SEC |
| Aug 16, 2016 | Robin Howard W | President & CEO | Form 4 sale | 11,817 | $208k | 8.4% | Plan not stated | SEC |
| Aug 16, 2016 | Labrucherie Gil M | SVP & Chief Financial Officer | Form 4 sale | 3,305 | $58k | 5.9% | Plan not stated | SEC |
| Aug 16, 2016 | Hora Maninder | SVP Pharma Dev & Mfg Ops | Form 4 sale | 3,305 | $58k | 6.0% | Plan not stated | SEC |
| Aug 16, 2016 | Gergel Ivan P. | SVP & Chief Medical Officer | Form 4 sale | 1,685 | $30k | 5.8% | Plan not stated | SEC |
| Aug 16, 2016 | Doberstein Stephen K | SVP & Chief Scientific Officer | Form 4 sale | 1,336 | $23k | 6.6% | Plan not stated | SEC |
| Aug 1, 2016 | Chess Robert | Director | Form 4 sale | 5,000 | $86k | 1.9% | Plan not stated | SEC |
| Jul 11, 2016 | Thomsen Jillian B. | SVP & Chief Accounting Officer | Form 4 sale | 100,000 | $1.5M | 93.6% | Unusual | SEC |
| Jul 1, 2016 | Chess Robert | Director | Form 4 sale | 5,000 | $71k | 1.9% | Plan not stated | SEC |
| Jun 1, 2016 | Chess Robert | Director | Form 4 sale | 5,000 | $78k | 1.9% | Plan not stated | SEC |
| May 17, 2016 | Nicholson John | SVP & Chief Financial Officer | Form 4 sale | 856 | $12k | 1.1% | Plan not stated | SEC |
| May 17, 2016 | Robin Howard W | President & CEO | Form 4 sale | 2,170 | $29k | 11.4% | Plan not stated | SEC |
| May 17, 2016 | Doberstein Stephen K | SVP & Chief Scientific Officer | Form 4 sale | 339 | $5k | 24.9% | Plan not stated | SEC |
| May 17, 2016 | Gergel Ivan P. | SVP & Chief Medical Officer | Form 4 sale | 432 | $6k | 22.2% | Plan not stated | SEC |
| May 17, 2016 | Hora Maninder | SVP Pharma Dev & Mfg Ops | Form 4 sale | 835 | $11k | 10.5% | Plan not stated | SEC |
| May 17, 2016 | Labrucherie Gil M | SVP & General Counsel | Form 4 sale | 836 | $11k | 9.5% | Plan not stated | SEC |
| May 17, 2016 | Thomsen Jillian B. | SVP & Chief Accounting Officer | Form 4 sale | 724 | $10k | 10.3% | Plan not stated | SEC |
| Apr 25, 2016 | Lingnau Lutz | Director | Form 4 sale | 15,000 | $244k | 47.7% | Unusual | SEC |
| Mar 9, 2016 | Thomsen Jillian B. | SVP & Chief Accounting Officer | Form 4 sale | 15,000 | $177k | 74.4% | Unusual | SEC |
| Feb 17, 2016 | Gergel Ivan P. | SVP & Chief Medical Officer | Form 4 sale | 556 | $7k | 44.5% | Unusual | SEC |
| Feb 17, 2016 | Nicholson John | SVP & Chief Financial Officer | Form 4 sale | 963 | $11k | 1.2% | Plan not stated | SEC |
| Feb 17, 2016 | Robin Howard W | President & CEO | Form 4 sale | 2,147 | $26k | 13.7% | Plan not stated | SEC |
| Feb 17, 2016 | Doberstein Stephen K | SVP & Chief Scientific Officer | Form 4 sale | 390 | $5k | 44.6% | Unusual | SEC |
| Feb 17, 2016 | Thomsen Jillian B. | SVP & Chief Accounting Officer | Form 4 sale | 716 | $9k | 12.2% | Plan not stated | SEC |
| Feb 17, 2016 | Labrucherie Gil M | SVP & General Counsel | Form 4 sale | 827 | $10k | 11.2% | Plan not stated | SEC |
| Feb 17, 2016 | Hora Maninder | SVP Pharma Dev & Mfg Ops | Form 4 sale | 963 | $11k | 14.2% | Plan not stated | SEC |
| Feb 10, 2016 | Labrucherie Gil M | SVP & General Counsel | Form 4 sale | 11,666 | $134k | 69.0% | Unusual | SEC |
| Feb 10, 2016 | Thomsen Jillian B. | SVP & Chief Accounting Officer | Form 4 sale | 15,000 | $172k | 79.0% | Unusual | SEC |
| Feb 10, 2016 | Robin Howard W | President & CEO | Form 4 sale | 66,666 | $766k | 87.0% | Unusual | SEC |
| Jan 20, 2016 | Lingnau Lutz | Director | Form 4 sale | 15,000 | $218k | 47.7% | Unusual | SEC |
| Jan 19, 2016 | Thomsen Jillian B. | SVP & Chief Accounting Officer | Form 4 sale | 15,000 | $212k | 79.0% | Unusual | SEC |
| Jan 19, 2016 | Robin Howard W | President & CEO | Form 4 sale | 66,667 | $941k | 87.0% | Unusual | SEC |
| Jan 19, 2016 | Labrucherie Gil M | SVP & General Counsel | Form 4 sale | 11,667 | $165k | 69.0% | Unusual | SEC |
| Dec 4, 2015 | Kuebler Christopher A | Director | Form 4 sale | 15,000 | $237k | 42.9% | Unusual | SEC |
| Dec 3, 2015 | Labrucherie Gil M | SVP & General Counsel | Form 4 sale | 45,001 | $714k | 89.6% | Unusual | SEC |
| Dec 3, 2015 | Robin Howard W | President & CEO | Form 4 sale | 125,001 | $2M | 92.6% | Unusual | SEC |
| Dec 3, 2015 | Thomsen Jillian B. | SVP & Chief Accounting Officer | Form 4 sale | 15,000 | $238k | 79.0% | Unusual | SEC |
| Nov 20, 2015 | Wang Susan | Director | Form 4 sale | 85,000 | $1.3M | 81.0% | Unusual | SEC |
| Nov 11, 2015 | Robin Howard W | President & CEO | Form 4 sale | 125,000 | $1.7M | 92.6% | Unusual | SEC |
| Nov 11, 2015 | Labrucherie Gil M | SVP & General Counsel | Form 4 sale | 45,000 | $608k | 90.5% | Unusual | SEC |
| Nov 11, 2015 | Thomsen Jillian B. | SVP & Chief Accounting Officer | Form 4 sale | 15,000 | $203k | 81.1% | Unusual | SEC |
| Oct 28, 2015 | Lingnau Lutz | Director | Form 4 sale | 12,500 | $150k | 43.2% | Unusual | SEC |
| Oct 6, 2015 | Robin Howard W | President & CEO | Form 4 sale | 125,000 | $1.4M | 92.6% | Unusual | SEC |
| Oct 6, 2015 | Labrucherie Gil M | SVP & General Counsel | Form 4 sale | 45,000 | $495k | 90.5% | Unusual | SEC |
| Oct 6, 2015 | Thomsen Jillian B. | SVP & Chief Accounting Officer | Form 4 sale | 15,000 | $165k | 81.1% | Unusual | SEC |
| Sep 23, 2015 | Thomsen Jillian B. | SVP & Chief Accounting Officer | Form 4 sale | 10,000 | $130k | 74.1% | Unusual | SEC |
| Sep 23, 2015 | Robin Howard W | President & CEO | Form 4 sale | 124,999 | $1.6M | 92.6% | Unusual | SEC |
| Sep 23, 2015 | Labrucherie Gil M | SVP & General Counsel | Form 4 sale | 44,999 | $587k | 90.5% | Unusual | SEC |
| Aug 13, 2015 | Labrucherie Gil M | SVP & General Counsel | Form 4 sale | 33,333 | $363k | 87.5% | Unusual | SEC |
| Aug 13, 2015 | Robin Howard W | President & CEO | Form 4 sale | 58,333 | $635k | 85.4% | Unusual | SEC |
| Aug 12, 2015 | Nicholson John | SVP & Chief Financial Officer | Form 4 sale | 319,884 | $3.4M | 81.0% | Unusual | SEC |
| Jul 14, 2015 | Robin Howard W | President & CEO | Form 4 sale | 58,334 | $687k | 85.4% | Unusual | SEC |
| Jul 14, 2015 | Labrucherie Gil M | SVP & General Counsel | Form 4 sale | 33,334 | $393k | 88.7% | Unusual | SEC |
| Jun 29, 2015 | Wang Susan | Director | Form 4 sale | 30,000 | $381k | 60.0% | Unusual | SEC |
| Jun 19, 2015 | Chess Robert | Director | Form 4 sale | 15,000 | $177k | 5.4% | Plan not stated | SEC |
| Jun 15, 2015 | Lingnau Lutz | Director | Form 4 sale | 25,000 | $279k | 60.3% | Unusual | SEC |
| Jan 13, 2015 | Kuebler Christopher A | Director | Form 4 sale | 15,000 | $240k | 42.9% | Unusual | SEC |
| Dec 29, 2014 | Chess Robert | Director | Form 4 sale | 29,500 | $453k | 10.2% | Plan not stated | SEC |
| Dec 22, 2014 | Thomsen Jillian B. | SVP & Chief Accounting Officer | Form 4 sale | 5,000 | $78k | 62.5% | Unusual | SEC |
| Dec 1, 2014 | Labrucherie Gil M | SVP & General Counsel | Form 4 sale | 120,000 | $2M | 96.6% | Unusual | SEC |
| Dec 1, 2014 | Robin Howard W | President & CEO | Form 4 sale | 350,000 | $6M | 97.2% | Unusual | SEC |
| Nov 25, 2014 | Robin Howard W | President & CEO | Form 4 sale | 600,000 | $9.1M | 98.4% | Unusual | SEC |
| Nov 24, 2014 | Labrucherie Gil M | SVP & General Counsel | Form 4 sale | 10,500 | $158k | 73.7% | Unusual | SEC |
| Nov 24, 2014 | Lingnau Lutz | Director | Form 4 sale | 15,000 | $225k | 47.7% | Unusual | SEC |
| Nov 3, 2014 | Labrucherie Gil M | SVP & General Counsel | Form 4 sale | 9,900 | $136k | 72.5% | Unusual | SEC |
| Aug 5, 2013 | Kuebler Christopher A | Director | Form 4 sale | 12,500 | $155k | 38.5% | Unusual | SEC |
| Aug 5, 2013 | Whitfield Roy A | Director | Form 4 sale | 12,500 | $155k | 38.5% | Unusual | SEC |
| Sep 27, 2012 | Kuebler Christopher A | Director | Form 4 sale | 12,500 | $133k | 38.5% | Unusual | SEC |
| Jul 13, 2012 | Chess Robert | Director | Form 4 sale | 24,001 | $204k | 8.4% | Plan not stated | SEC |
| Mar 8, 2011 | Chess Robert | Director | Form 4 sale | 4,500 | $41k | 1.7% | Plan not stated | SEC |
| May 10, 2010 | Chess Robert | Director | Form 4 sale | 35,000 | $488k | 12.1% | Plan not stated | SEC |
| May 12, 2009 | Labrucherie Gil M | SVP & General Counsel | Form 4 sale | 395 | $2k | 12.9% | Plan not stated | SEC |
| May 12, 2009 | Thomsen Jillian B. | VP & Chief Accounting Officer | Form 4 sale | 201 | $1k | 9.3% | Plan not stated | SEC |
| Nov 14, 2008 | Labrucherie Gil M | SVP & General Counsel | Form 4 sale | 401 | $2k | 16.9% | Plan not stated | SEC |
| Nov 14, 2008 | Thomsen Jillian B. | VP & Chief Accounting Officer | Form 4 sale | 203 | $887 | 11.2% | Plan not stated | SEC |
| Nov 14, 2008 | Patton John Stuart | Chief Scientific Officer | Form 4 sale | 760 | $3k | 0.2% | Plan not stated | SEC |
| Mar 22, 2007 | Chess Robert | Director | Form 4 sale | 17,700 | $216k | 6.8% | Plan not stated | SEC |
| Jan 8, 2007 | Chess Robert | Chairman, Pres. & CEO | Form 4 sale | 3,592 | $52k | 1.7% | Plan not stated | SEC |
| May 15, 2006 | Patton John Stuart | Chief Scientific Officer | Form 4 sale | 1,633 | $33k | 72.7% | Unusual | SEC |
| Mar 23, 2006 | Gill Ajit | Other | Form 4 sale | 3,545 | $70k | 3.9% | Plan not stated | SEC |
| Mar 10, 2006 | Bansal Ajay | Other | Form 4 sale | 5,167 | $103k | 50.0% | Unusual | SEC |
| Mar 7, 2006 | Chess Robert | Executive Chairman | Form 4 sale | 2,210 | $44k | 1.1% | Plan not stated | SEC |
| Mar 7, 2006 | Patton John Stuart | Chief Scientific Officer | Form 4 sale | 3,859 | $76k | 0.7% | Plan not stated | SEC |
| Jan 27, 2006 | Gill Ajit | President & CEO | Form 4 sale | 40,000 | $883k | 32.9% | Unusual | SEC |
| Jan 27, 2006 | Patton John Stuart | Chief Scientific Officer | Form 4 sale | 20,000 | $440k | 3.5% | Plan not stated | SEC |
| Jan 13, 2006 | Patton John Stuart | Chief Scientific Officer | Form 4 sale | 20,000 | $401k | 3.7% | Plan not stated | SEC |